These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31987665)

  • 1. Prevalence of Anderson-Fabry disease in a cohort with unexplained late gadolinium enhancement on cardiac MRI.
    Moonen A; Lal S; Ingles J; Yeates L; Semsarian C; Puranik R
    Int J Cardiol; 2020 Apr; 304():122-124. PubMed ID: 31987665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical findings of gadolinium-enhanced cardiac magnetic resonance in Fabry patients.
    Nojiri A; Anan I; Morimoto S; Kawai M; Sakuma T; Kobayashi M; Kobayashi H; Ida H; Ohashi T; Eto Y; Shibata T; Yoshimura M; Hongo K
    J Cardiol; 2020 Jan; 75(1):27-33. PubMed ID: 31623930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac imaging and biomarkers for assessing myocardial fibrosis in children with hypertrophic cardiomyopathy.
    Kirmani S; Woodard PK; Shi L; Hamza TH; Canter CE; Colan SD; Pahl E; Towbin JA; Webber SA; Rossano JW; Everitt MD; Molina KM; Kantor PF; Jefferies JL; Feingold B; Addonizio LJ; Ware SM; Chung WK; Ballweg JA; Lee TM; Bansal N; Razoky H; Czachor J; Lunze FI; Marcus E; Commean P; Wilkinson JD; Lipshultz SE
    Am Heart J; 2023 Oct; 264():153-162. PubMed ID: 37315879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial perfusion reserve quantified by cardiac magnetic resonance imaging is associated with late gadolinium enhancement in hypertrophic cardiomyopathy.
    Tezuka D; Kosuge H; Terashima M; Koyama N; Kishida T; Tada Y; Suzuki JI; Sasano T; Ashikaga T; Hirao K; Isobe M
    Heart Vessels; 2018 May; 33(5):513-520. PubMed ID: 29168014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative diffusion-weighted magnetic resonance imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy compared with T1 mapping.
    Wu LM; Chen BH; Yao QY; Ou YR; Wu R; Jiang M; Hu J; An DA; Xu JR
    Int J Cardiovasc Imaging; 2016 Aug; 32(8):1289-97. PubMed ID: 27198892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR.
    Kozor R; Grieve SM; Tchan MC; Callaghan F; Hamilton-Craig C; Denaro C; Moon JC; Figtree GA
    Heart; 2016 Feb; 102(4):298-302. PubMed ID: 26729695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late gadolinium enhancement on CMRI in patients with LV noncompaction: An overestimated phenomenon?
    Asmakutlu O; Alis D; Topel C; Sahin A
    Clin Imaging; 2020 Oct; 66():121-126. PubMed ID: 32480266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of (99m)Tc-MIBI SPECT/18F-FDG PET imaging and cardiac magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy: assessment of cardiac function and myocardial injury.
    Wang L; Yan C; Zhao S; Fang W
    Clin Nucl Med; 2012 Dec; 37(12):1163-9. PubMed ID: 23154474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.
    Liu D; Ma X; Liu J; Zhao L; Chen H; Xu L; Sun Z; Fan Z
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1191-1200. PubMed ID: 28289991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy--comparison with late enhancement quantification.
    Małek ŁA; Werys K; Kłopotowski M; Śpiewak M; Miłosz-Wieczorek B; Mazurkiewicz Ł; Petryka-Mazurkiewicz J; Marczak M; Witkowski A
    Magn Reson Imaging; 2015 Jul; 33(6):718-24. PubMed ID: 25863138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome.
    Machii M; Satoh H; Shiraki K; Saotome M; Urushida T; Katoh H; Takehara Y; Sakahara H; Ohtani H; Wakabayashi Y; Ukigai H; Tawarahara K; Hayashi H
    Magn Reson Imaging; 2014 Feb; 32(2):118-24. PubMed ID: 24315973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis.
    Nucifora G; Muser D; Gianfagna P; Morocutti G; Proclemer A
    Int J Cardiovasc Imaging; 2015 Dec; 31(8):1603-10. PubMed ID: 26210792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial Fibrosis in Hypertrophic Cardiomyopathy: Volumetric Assessment of Late Enhancement Provided by Cardiac Computed Tomography.
    Langer C; Schaefer P; Lutz M; Eden M; Hohnhorst M; Harders H; Faber L; Jansen O; Both M; Frey N
    J Comput Assist Tomogr; 2015; 39(5):797-803. PubMed ID: 26125299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study.
    Weidemann F; Beer M; Kralewski M; Siwy J; Kampmann C
    Mol Genet Metab; 2019 Feb; 126(2):169-182. PubMed ID: 30594474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.
    Yin L; Xu HY; Zheng SS; Zhu Y; Xiao JX; Zhou W; Yu SS; Gong LG
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1949-1959. PubMed ID: 28612277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Late gadolinium enhancement and T1 mapping for the diagnosis of cardiac amyloidosis].
    Cui Q; Yu J; Shen W
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Dec; 31(12):1538-1541. PubMed ID: 32029045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy.
    Latif SR; Nguyen VQ; Peters DC; Soufer A; Henry ML; Grunseich K; Testani J; Hur DJ; Huber S; Mojibian H; Dicks D; Sinusas AJ; Meadows JL; Papoutsidakis N; Jacoby D; Baldassarre LA
    Int J Cardiovasc Imaging; 2019 Jul; 35(7):1309-1318. PubMed ID: 30790116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.
    Choi HM; Kim KH; Lee JM; Yoon YE; Lee SP; Park EA; Lee W; Kim YJ; Cho GY; Sohn DW; Kim HK
    Heart; 2015 Jun; 101(11):870-6. PubMed ID: 25897040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
    Green JJ; Berger JS; Kramer CM; Salerno M
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.